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The consumption of water contaminated by
naturally occurring arsenic poses a serious
threat to human health worldwide (Gebel
1999; Nickson et al. 1998). Arsenic causes a
wide range of human ailments, including can-
cer, and vascular diseases such as peripheral
and cardiovascular disease, arteriosclerosis,
Raynaud’s syndrome, and hypertension (Chen
1990; Engel et al. 1994; Rahman et al. 1999;
Wang et al. 2002; Yu et al. 2002). Because the
precise mechanisms of arsenic toxicity are still
largely undefined, a potentially important
remedial action is the termination of further
exposure by providing safe drinking water.
However, limited data are available on the
reversibility of chronic arsenosis in humans.
Our previous studies indicated that
chronic exposure to arsenic through drinking
water can induce systematic nitric oxide dys-
function, and the impaired NO signaling or
bioactivity contributes to arsenic-associated
vascular diseases (Pi et al. 2000, 2003;
Kumagai and Pi 2004). NO bioactivity is a
critical factor in vascular tone, and its impair-
ment can lead to vaso-occlusive diseases (Ganz
and Vita 2003). Impaired NO bioactivity con-
tributes, at least in part, to vascular diseases in
chronic arsenosis patients (Pi et al. 2000). NO
produced endogenously from L-arginine by
NO synthases is involved in many physiologic
and pathophysiologic processes (Ganz and
Vita 2003), and reduced NO production in
turn is related to vascular endothelial cell dys-
function (Gewaltig and Kojda 2002). Among
the multiple activities of NO, the homeostatic
control of the vascular endothelium is directly
connected with the activation of soluble
guanylate cyclase and the production of cyclic
3´,5´-guanosine monophosphate (cGMP), a
critical second messenger of the NO system
(Gewaltig and Kojda 2002). Urinary excretion
cGMP has been used as a reliable biomarker
for endogenous NO production and endothe-
lial cell function (Boger et al. 1997; Cui et al.
2004), and reduced cGMP production is
thought to be a biochemical indicator of
impaired NO production and peripheral vas-
cular disease (Boger et al. 1997). Therefore, in
this follow-up study, we evaluated the impact
of intake reduction on chronic arsenic intoxi-
cation by investigating urinary excretion of
cGMP and peripheral vascular function in
arsenosis patients before and after they were
supplied with low-arsenic drinking water.
Methods
Subjects. This study was carried out in
Gangfangying village, Baotou, Inner Mongolia,
China, where high concentrations of arsenic
(up to 1,790 µg/L) were present in tube-well
water from the end of the 1970s to August
1999. At this point, an alternative commu-
nity water supply with a drastically lower
arsenic level (37 µg/L) was installed. The
investigations were conducted in August 1999,
just before the new water system was installed,
and again in September 2000, 13 months after
the switch to less-contaminated drinking
water. We obtained informed consent from all
participants. Two certiﬁed dermatologists and
two trained physicians performed physical
examinations and administered a standardized
questionnaire interview at both time points. A
total of 54 volunteer residents (24 males and
30 females, 8–65 years of age; mean age,
36.2 years) who participated in the two surveys
in 1999 and 2000 and provided urine samples
were enrolled in the present study. Some
patients were excluded from this study because
of unclear exposure history (14 cases) or
because they provided no urine samples in
2000 (10 cases). Before arsenic remediation,
29 of the subjects were identified as having
skin lesions typical of arsenosis, which include
verrucous hyperkeratoses of the palms and
soles of the feet and hypo- and hyper-
pigmentation in the trunk area (Pi et al. 2002).
These symptoms were predominantly found in
males (18/29 cases; 62%). In addition, there
were 16 reports of cold-weather–associated
pain and coldness in the extremities of the feet
Environmental Health Perspectives • VOLUME 113 | NUMBER 3 | March 2005 339
Address correspondence to Y. Kumagai, Department of
Environmental Medicine, Doctoral Programs in
Medical Sciences, Graduate School of Comprehensive
Human Sciences, University of Tsukuba, 1-1-1
Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Telephone/Fax: 81-29-853-3133. E-mail: yk-em-tu@
md.tsukuba.ac.jp
We thank N. Shimojo (Institute of Community
Medicine, University of Tsukuba) for his encourage-
ment on this project; B. Li, C. Qian, S.T. Shi, S. Liu,
X. Li, and S.T. Ben (School of Public Health, China
Medical University) and C.Z. Zhang (Erdeng E
Health Department of Baotou, Inner Mongolia,
China) for their excellent contributions to this work.
We also thank L.K. Keefer, J. Liu, and E. Leslie for
their critical reviews of the manuscript.
This work was supported in part by funding from
the Japan-China Medical Association to Y.K. by a
China Nature Science Foundation grant (no.
30000142 to J.P.), and by Grants-in-Aids (nos.
15406004 and 13576029 to Y.K. and no. 13576018
to H.Y.) for scientiﬁc research from the Ministry of
Education, Science and Culture of Japan. 
The authors declare they have no competing ﬁnancial
interests.
Received 2 August 2004; accepted 9 December 2004.
Vascular Dysfunction in Patients with Chronic Arsenosis Can Be Reversed by
Reduction of Arsenic Exposure 
Jingbo Pi,1,2 Hiroshi Yamauchi,3 Guifan Sun,4 Takahiko Yoshida,5 Hiroyuki Aikawa,6 Wataru Fujimoto,7
Hiroyasu Iso,8 Renzhe Cui,8 Michael P. Waalkes,2 and Yoshito Kumagai9
1Graduate School of Medical Sciences, University of Tsukuba, Tsukuba, Japan; 2Laboratory of Comparative Carcinogenesis, National
Cancer Institute, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA;
3Department of Preventive Medicine, St. Marianna University School of Medicine, Kawasaki, Japan; 4Department of Labor Hygiene and
Occupational Health, School of Public Health, China Medical University, Shenyang, China; 5Department of Public Health, Asahikawa
Medical College, Asahikawa, Japan; 6Department of Environmental Health, Tokai University School of Medicine, Isehara, Japan;
7Department of Dermatology, Kawasaki Medical School, Kurashiki, Japan, 8Department of Public Health, and 9Department of
Environmental Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan
Chronic arsenic exposure causes vascular diseases associated with systematic dysfunction of endoge-
nous nitric oxide. Replacement of heavily arsenic-contaminated drinking water with low-arsenic
water is a potential intervention strategy for arsenosis, although the reversibility of arsenic intoxica-
tion has not established. In the present study, we examined urinary excretion of cyclic guanosine
3´,5´-monophosphate (cGMP), a second messenger of the vasoactive effects of nitric oxide, and
signs and symptoms for peripheral vascular function in 54 arsenosis patients before and after they
were supplied with low-arsenic drinking water in an endemic area of chronic arsenic poisoning in
Inner Mongolia, China. The arsenosis patients showed a marked decrease in urinary excretion of
cGMP (mean ± SEM: male, 37.0 ± 6.1; female, 37.2 ± 5.4 nmol/mmol creatinine), and a 13-month
period of consuming low-arsenic drinking water reversed this trend (male, 68.0 ± 5.6; female, 70.6
± 3.0 nmol/mmol creatinine) and improved peripheral vascular response to cold stress. Our inter-
vention study indicates that peripheral vascular disease in arsenosis patients can be reversed by
exposure cessation and has important implications for the public health approach to arsenic expo-
sure. Key words: arsenic, cGMP, endothelial dysfunction, intervention study, nitric oxide. Environ
Health Perspect 113:339–341 (2005). doi:10.1289/ehp.7471 available via http://dx.doi.org/ [Online
9 December 2004]
Environmental Medicine Articleand hands and/or white fingers, which are
regarded as indicators of arsenic-induced
peripheral vascular dysfunction. There were no
cases of hypertension or overt cardiac dysfunc-
tion. We collected fasting peripheral venous
blood and morning urine samples for arsenic
and/or cGMP analysis. Additionally, for a ref-
erence control, we collected 1,132 urine sam-
ples from a general population of Japanese men
and women (40–65 years of age), living in the
two farming communities of Ikawa and
Kyowa, known to have minimal exposure to
environmental inorganic arsenic.
Evaluation of arsenic poisoning. We evalu-
ated peripheral vascular response to cold stress
by the difference of ﬁnger systolic blood pres-
sure before and after ice-water immersion,
which made the surface temperature of the ﬁn-
ger decrease by 10ºC. Finger systolic blood
pressure was determined by a finger blood
pressure monitor (HEM-808F; Omron,
Matsusaka, Japan). We measured skin temper-
ature using a Tele-thermometer (WMZ-03,
Shanghai Instruments, Shanghai, China).
Arsenic content in biological samples. We
determined arsenic levels in water and biologi-
cal samples by atomic absorption spectro-
photometry (AA-6800G-ASA-2sp; Shimadzu,
Kyoto, Japan) according to our previously
reported method (Pi et al. 2003). The detection
limit of this method was 1 ng, and the coefﬁ-
cient of variation was < 5%. For standard refer-
ence material, we used oyster tissue (no. 1566)
from the National Institute of Standards and
Technology (Gaithersburg, MD, USA). 
Urinary cGMP level. We used an
125I-labeled cGMP radioimmunoassay kit
(Amersham, Buckinghamshire, UK) with a
detection limit of 256 fmol/ml to measure
urinary cGMP. The interassay coefficient of
variation was 3.2% (n = 8). To control the
differences in renal function, we divided the
urinary excretion of cGMP by the urinary cre-
atinine concentration (expressed in nanomoles
cGMP per millimoles of creatinine) (Boger
et al. 1997). Urinary creatinine levels were
determined using a creatinine test kit (Wako
Pure Chemical Industries, Osaka, Japan). For
each subject, we determined the urinary
cGMP excretion level and creatinine twice and
used the average value as the final measure-
ment. In the present study, we investigated the
effects of arsenic exposure reduction among
chronic arsenosis patients based on urinary
excretion of cGMP as an indicator of vascular
dysfunction. We did not determine the levels
of nitrite/nitrate, which are stable NO
metabolites, as an alternative index of NO
function because several of the tube-wells were
contaminated with high levels of nitrite and/or
nitrate, which would have distorted these data. 
Statistical analysis. Data are expressed as
mean ± SEM in all cases. Comparisons
between data obtained before and after the
water switch were performed with a two-tailed,
paired Student’s t-test. A value of p = 0.05 was
considered statistically signiﬁcant. 
Results and Discussion
Table 1 shows that the mean arsenic level in
the well water consumed by the 54 subjects
from the end of the 1970s to August 1999
(before remediation) was 180 µg/L. In the
nearly 20 years of exposure, all of the house-
holds enrolled in this study had shared
between two and six of these water sources.
The arsenic level of the new water supply was
37 µg/L, lower than the World Health
Organization (WHO) maximum permissible
limit of 50 µg/L for drinking water (WHO
1984). The 13-month exposure reduction
markedly decreased the arsenic levels in biolog-
ical samples, including urine and blood sam-
ples, in a sex-independent fashion (Table 1),
showing that the new low-arsenic water supply
effectively reduced the body burden of arsenic. 
As shown in Table 2 and Figure 1, the uri-
nary cGMP levels in all age groups of both
sexes were signiﬁcantly depressed before reme-
diation when high levels of arsenic were con-
sumed. This finding was supported by the
work of Lee et al. (2003), who reported that
arsenite can dramatically inhibit cGMP accu-
mulation in isolated aortic rings of rats. After
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Figure 1. Urinary cGMP excretion in male (n = 24) and female (n = 30) untreated chronic arsenosis patients
before and after the switch to low-arsenic drinking water. Water remediation reversed the arsenic-
induced suppression of cGMP production in both males (p = 0.0012) and females (p < 0.0001). 
Table 2. Urinary cGMP excretion (nmol/mmol creatinine) before and after switching to low-arsenic drink-
ing water. 
Before remediation After remediation
Age (years)a Males Females Males Females
8–13 22.1 ± 3.0 27.2 ± 1.7 73.7 ± 19.8* 66.8 ± 22.4*
(n = 3) (n = 4) (n = 3) (n = 4) 
21–40 29.6 ± 3.6 33.3 ± 5.5 60.1 ± 3.1* 76.8 ± 7.8*
(n = 6) (n = 15) (n = 6) (n = 15)
41–65 45.1 ± 10.2 42.9 ± 11.1 67.2 ± 6.5* 69.9 ± 8.5*
(n = 15) (n = 11) (n = 15) (n = 11)
Data expressed as mean ± SEM. 
aAge in August 1999. *Signiﬁcantly different (p < 0.05) from measurement taken in August 1999, immediately before the
introduction of low-arsenic drinking water. 
Table 1. Arsenic levels in drinking water and biological samples before and after drinking water remediation.
Before remediation After remediation
Males Females Males Females
Biological samples
Blood (µg/L)a 9.89 ± 0.21 6.10 ± 0.79 2.52 ± 0.23* 1.83 ± 0.19*
(n = 22) (n = 23) (n = 22) (n = 23)
Urine (µg/g Cr) 424.5 ± 122.9 292.5 ± 66.6 177.2 ± 37.7* 161.5 ± 32.7*
(n = 24) (n = 30) (n = 24) (n = 30)
Drinking water (µg/L) 180 ± 60 38
Cr, creatinine. Data expressed as mean ± SEM. Before remediation, n = 37 community wells; after remediation, n = 1 low-
arsenic community well.
aNine blood samples were not available. *Signiﬁcantly reduced (p < 0.05) compared with appropriate sex-matched popu-
lation values from before remediation. the 13-month arsenic exposure reduction, uri-
nary cGMP levels increased to normal, as
compared to the Japanese general population-
based control values of 57.3 ± 2.1 nmol
cGMP/mmol of creatinine in males (n = 510;
40–65 years of age) and 70.6 ± 3.0 in females
(n = 622; 40–65 years of age) (Cui et al. 2004). 
In agreement with the recovery of the
arsenic-induced dysfunction of the NO/cGMP
system, as indicated by the increase in urinary
cGMP excretion, peripheral vascular response
to cold stress, measured as the difference in ﬁn-
ger systolic blood pressure before and after ice-
water immersion, was signiﬁcantly improved in
male arsenosis patients (Table 3). In female
arsenosis patients, although some improve-
ment in finger blood pressure response
occurred, it was not statistically significant
(Table 3). The difference between peripheral
vascular response to cold stress between male
and female patients before remediation was
also signiﬁcant (Table 3), which is consistent
with more severe exposure in males as evi-
denced by blood and urinary arsenic (Table 1)
and skin lesions. In addition, 3 of the
16 patients reporting cold-weather–associated
pain and coldness and/or white ﬁngers showed
improvement, although 12 patients had no
signiﬁcant change, and 1 patient became worse
(data not shown).
Replacement of drinking water heavily
contaminated with arsenic with low-arsenic
water is a potential intervention strategy to
minimize or reverse the adverse health effects
of this toxic inorganic element. Consistent
with our previous results (Pi et al. 2000),
male and female arsenosis patients in the pre-
sent study showed a marked depression in
urinary excretion of cGMP, and a 13-month
period of consuming low-arsenic drinking
water reversed this depression. In addition,
improved peripheral vascular response to cold
stress was clearly observed in male arsenosis
patients after consuming low-arsenic water
and tended to improve in females. Together,
these data suggest that long-term arsenic
exposure induces biochemical changes in the
vascular system and causes functional vascular
damage, which, at least in males, can be
reversed by limiting further arsenic intake.
Although cGMP production improved, it is
possible that females may need a longer
period of reduced arsenic exposure for vascu-
lar function to be completely restored. In
addition, before remediation, males had
much higher blood and urinary arsenic levels
and showed a higher rate of arsenic-induced
skin lesions, indicating more severe intoxica-
tion. Thus, improvement of the symptoms of
arsenic poisoning may be more readily
observed in males.
In conclusion, a 13-month arsenic expo-
sure reduction effectively reverses the arsenic-
induced impairment of the NO/cGMP
pathway in both males and females and
improves peripheral vascular function in males.
Additional comprehensive follow-up studies
are necessary to document the long-term
health beneﬁts of arsenic exposure reduction,
but the present results indicate the reduction of
arsenic exposure could be an important public
health strategy.
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Table 3. Peripheral vascular response to cold stress
before and after switching to low-arsenic drinking
water. 
Before After
Sex No. remediation remediation
Males 15 41.5 ± 5.8 26.0 ± 4.8*
Females 16 28.6 ± 3.4** 22.6 ± 4.3
Data expressed as mean ± SEM (mmHg). 
*Signiﬁcantly different (p < 0.05) from measurement taken
before remediation. **Signiﬁcantly different (p < 0.05) from
males before remediation.